Day: June 4, 2021

New York, June 04, 2021 (GLOBE NEWSWIRE) — Ventoux CCM Acquisition Corp. (the “Company”) received a standard notice on May 28, 2021 from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”), which stated that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) because it had not filed its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 with the Securities and Exchange Commission (“SEC”). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the SEC. On April 12, 2021, the staff of the SEC issued a public statement entitled “Staff Statement on Accounting and Reporting Considerations for Warrants Issued by Special Purpose Acquisition Companies (“SPACs”)” (the “Statement”), which provided guidance for all SPAC-related...

NOT FOR DISTRIBUTION IN THE UNITED STATES OR TO U.S. NEWSWIRE SERVICES MONTRÉAL, June 04, 2021 (GLOBE NEWSWIRE) — Goldstar Minerals Inc. (“Goldstar” or the “Corporation”) (TSX-V: GDM) is pleased to announce that it has closed a non-brokered private placement of $200,200 representing the first tranche of a flow-through share financing of up to $720,000. Under this first tranche, the Corporation issued 1,112,223 flow-through common shares (the “Flow-Through Shares”) at a price of $0.18 per share for gross proceeds of $200,200. The Flow-Through Shares issued pursuant to this private placement are subject to a four month hold period. The proceeds from the issuance of the Flow-Through Shares will be used to incur Canadian Exploration Expenses on properties of the Corporation located in the Province of Québec. An insider of the Corporation...

Houston, Texas, June 04, 2021 (GLOBE NEWSWIRE) —  Industrial Tech Acquisitions, Inc. (NASDAQ: ITAC) (the “Company”) today announced that on May 28, 2021, the Company received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) as a result of the Company’s failure to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the “Form 10-Q”) in a timely manner. The Notice advised the Company that it was not in compliance with Nasdaq’s continued listing requirements under the timely filing criteria established in Nasdaq Listing Rule 5250(c)(1).   On June 4, 2021, the Company filed its Form 10-Q and the Company believes it is now in compliance with the Nasdaq Listing Rules. As reported by the Company in its Form 12b-25 filed with the Securities and Exchange Commission...

New York, NY, June 04, 2021 (GLOBE NEWSWIRE) —  E.Merge Technology Acquisition Corp. (NASDAQ: ETAC) (the “Company”) today announced that it has received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the “Form 10-Q”) in a timely fashion. The Notice advised the Company that it was not in compliance with Nasdaq’s continued listing requirements under the timely filing criteria established in Nasdaq Listing Rule 5250(c)(1). As reported by the Company in its Form 12b-25 filed with the Securities and Exchange Commission (the “SEC”) on May 17, 2021, the Company was unable to file its Form 10-Q within the prescribed time period without unreasonable effort...

FORT LAUDERDALE, Fla., June 04, 2021 (GLOBE NEWSWIRE) — Priveterra Acquisition Corp. (the “Company”) today announced it received a notice on May 28, 2021 from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2021 (the “Quarterly Report”), the Company no longer complies with the continued listing requirements set forth in Nasdaq Listing Rule 5250(c)(1) (the “Rule”). The notice has no immediate impact on the listing of the Company’s securities, which will continue to trade on the Nasdaq, subject to the Company’s compliance with other applicable continued listing requirements. As previously disclosed on May 17, 2021 in the Form 12b-25 Notification of Late Filing filed by Priveterra Acquisition Corp. (the “Company”)...

Burlington, MA, June 04, 2021 (GLOBE NEWSWIRE) — East Stone Acquisition Corporation (Nasdaq: ESSCU) (the “Company”) today announced that it has received a notice (“Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) as a result of its failure to file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 (the “Form 10-Q”) in a timely fashion. The Notice advised the Company that it was not in compliance with Nasdaq’s continued listing requirements under the timely filing criteria established in Nasdaq Listing Rule 5250(c)(1). As reported by the Company in its Form 12b-25 filed with the Securities and Exchange Commission (the “SEC”) on May 17, 2021, the Company was unable to file its Form 10-Q within the prescribed time period without unreasonable effort...

Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate half-life extension, target engagement and T cell activationCytokine release syndrome observed and manageable, with low incidence of severe CRSManagement to host webcast and conference call to review the interim data presented at ASCO and provide a pipeline update today at 4 p.m. ET /1 p.m. PTSOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today provided a pipeline update on its four clinical stage programs, including updating the interim data presented earlier today at ASCO from the ongoing dose escalation...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 04, 2021 (GLOBE NEWSWIRE) — P2 Gold Inc. (“P2” or the “Company”) (TSX-V:PGLD) reports it has closed the non-brokered flow-through private placement (the “Private Placement”) (see P2’s news release dated May 19, 2021) for gross proceeds of approximately $1.75 million. In closing the Private Placement, the Company issued 2,917,170 flow-through units (the “Units”) of the Company at a price of $0.60 per Unit for gross proceeds of $1,750,302. Each Unit consists of one flow-through common share in the capital of the Company (a “Flow-Through Share”) and one non-flow-through common share purchase warrant (a “Warrant”). The Flow-Through Shares qualify as “flow-through shares” for purposes of the Income Tax...

A166 (ASCO Abstract #1024) is a third generation antibody drug conjugate (ADC) against HER2-positive breast cancer with Levena’s proprietary tubulin inhibitor Duo-5 toxin, cleavable linker and site-specific K-Lock™ conjugation chemistry. In this Phase 1 Study, A166 demonstrated a manageable safety profile and high stability in circulation with much lower acute hematological and gastrointestinal toxicities compared to commercial products. A166 has also demonstrated promising antitumor activity with clinically meaningful responses in heavily pretreated subjects with HER2-positive breast cancer. At a dose of 6.0 mg/kg, A166 demonstrated an 71.4% ORR as compared to 60.9% ORR from its major competitor DS-8201 at 5.4 mg/kg.SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”)...